• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

DEA Extends COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications for 6 Months

by Jasmine Pennic 05/09/2023 Leave a Comment

DEA Extends COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications for 6 Months

What You Should Know:

  • Today, the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued the “Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” – a temporary rule that extends telemedicine flexibilities adopted during the COVID-19 public health emergency (PHE).
  • ·         The temporary rule will take effect on May 11, 2023, and extends the full set of telemedicine flexibilities adopted during the COVID-19 public health emergency for six months – through November 11, 2023. For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding the prescription of controlled medications established during the COVID-19 PHE will be extended for one year – through November 11, 2024.

Background

On March 1, 2023, DEA, in concert with HHS, issued notices of proposed rulemakings (NPRM) to allow for prescribing of certain controlled medications via telemedicine without an in-person medical evaluation of the patient under circumstances that are consistent with public health, safety, and effective controls against diversion. The NPRMs received over 38,000 comments from the public and DEA, in collaboration with SAMHSA, is actively reviewing input in order to develop a permanent rule.

Tagged With: Coronavirus (COVID-19), HHS, Mental Health, Public Health, Substance Abuse, telemedicine

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

How to Build Hybrid Care Models Around Remote Patient Monitoring

How to Build Hybrid Care Models Around Remote Patient Monitoring

Most Popular

M&A: MultiPlan Acquires Benefits Science LLC for $160M

M&A: MultiPlan Acquires Benefits Science LLC for $160M

CalmWave, Inc.: Leveraging AI Technologies to Reduce Alarm Fatigue

Q/A: CalmWave CEO Talks Leveraging AI to Reduce Alarm Fatigue

Workplace Safety: The Most Important KPI for Healthcare Leaders Today

Elevating Workplace Safety to Combat Healthcare Violence Against Workers

Quest Diagnostics Acquires Haystack Oncology for $300M in Cash

Quest Diagnostics Acquires Haystack Oncology for $300M in Cash

M&A: Kaiser Acquires Geisinger, Forms Risant Health

M&A: Kaiser Acquires Geisinger, Forms Risant Health

HIMSS23 Executive Takeaways

5 Digital Health Executives Share Their Key Takeaways from HIMSS23

Philips & DoD Ink $10M Deal for AI-Wearable Disease Detection

Philips & DoD Ink $10M Deal for AI-Wearable Disease Detection

M&A: LexisNexis Risk Solutions Acquires Human API

M&A: LexisNexis Risk Solutions Acquires Human API

Availity

Availity Acquires Olive AI’s Utilization Management Solution and Business Unit

ChatGPT Has Potential to Help Cirrhosis, Liver Cancer Patients

ChatGPT Has Potential to Help Cirrhosis, Liver Cancer Patients, Cedars Sinai Study Reveals

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |